Evidence map›Paper›PMID 34302619›Full record

ReviewImmunologic research2021

Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy.

Yin Qianmei, Su Zehong, Wang Guang, Li Hui, Gaojian Lian

Abstract readReview
PubMed Publisher
In one paragraph

Review in Immunologic research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. The role and mechanism of IL‑35 in myasthenia gravis (Review).International journal of molecular medicine · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. CD4Trends in cancer · 2024
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yin QianmeiHengyang Medical School, University of South China, Hengyang City, 421001, Hunan Province, China.
Su ZehongHengyang Medical School, University of South China, Hengyang City, 421001, Hunan Province, China.
Wang GuangHengyang Medical School, University of South China, Hengyang City, 421001, Hunan Province, China.
Li HuiHengyang Medical School, University of South China, Hengyang City, 421001, Hunan Province, China.
Gaojian LianHengyang Medical School, University of South China, Hengyang City, 421001, Hunan Province, China. liansue@163.com.ORCID 0000-0002-2715-3715
University of South China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Th17 and Treg cells play an important role in regulating tissue inflammation and maintaining the stability of the immune system. They regulate inflammatory responses, participate in the occurrence and development of autoimmune diseases and tumors, and determine the disease progress. Malignant tumor is one of the diseases with the highest mortality rate in the world. However, the efficacy of traditional treatment is limited, so it is necessary to find safe and efficient treatment methods. Studies have shown that the balance of Th17/Treg cells plays a critical role in tumor progression. In this paper, we review the antitumor and tumor-suppressing effects of Th17/Treg cells, and new strategies for tumor therapy, combined with new research hotspots such as immune checkpoint therapy, miRNA-related gene therapy, and metabolic pathway regulation of Th17/Treg cell differentiation and tumor generation. The synergistic therapy is expected to be widely used in the future clinical practice, providing a new choice for the prevention and treatment of malignant tumors.

Indexed as

Disease SusceptibilityAnimalsBiomarkersCell CommunicationCell PlasticityCombined Modality TherapyDisease ManagementHumansLymphocyte ActivationLymphocytes, Tumor-InfiltratingNeoplasmsTh17 CellsT-Lymphocytes, RegulatoryT-Lymphocyte SubsetsTreatment OutcomeTumor MicroenvironmentBiomarkersCancer treatmentImmune checkpoint therapyMetabolic regulationTh17 cellsTreg cells

Identifiers

PMID34302619
OpenAlexW3184048362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.